Technical Analysis for CRBU - Caribou Biosciences, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
New 52 Week Closing Low | Bearish | 0.00% | |
Expansion Breakdown | Bearish Swing Setup | 0.00% | |
Bollinger Band Squeeze | Range Contraction | 0.00% | |
Earnings Movers | Other | 0.00% | |
BB Squeeze + Lower Band Touch | Range Contraction | 0.00% | |
BB Squeeze Started | Range Contraction | 0.00% | |
Gapped Down | Weakness | 0.00% | |
Lower Bollinger Band Touch | Weakness | 0.00% | |
Earnings Movers | Other | -6.17% | |
Gapped Up | Strength | -8.62% |
Alert | Time |
---|---|
60 Minute Opening Range Breakdown | about 19 hours ago |
Fell Below Lower Bollinger Band | about 19 hours ago |
Lower Bollinger Band Support | about 19 hours ago |
Down 1 ATR | about 19 hours ago |
2x Volume Pace | about 22 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 05/07/2024
Caribou Biosciences, Inc. Description
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma. The company also develops CB-012, an allogeneic anti-CD371 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia; and CB-020, an allogeneic CAR-NK cell therapy for the treatment of solid tumors. Caribou Biosciences has collaboration with AbbVie Manufacturing Management Unlimited Company to develop CAR-T cell therapies. The company was incorporated in 2011 and is headquartered in Berkeley, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biopharmaceutical Clinical Medicine Solid Tumors Cancer Immunotherapy Cell Therapy Cell Biology Leukemia Multiple Myeloma Breakthrough Therapy Hematologic Malignancies Chimeric Antigen Receptor T Cell T Cells CD19 Refractory Acute Myeloid Leukemia Treatment Of Relapsed Or Refractory Acute Myeloid Leukemia
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 8.5899 |
52 Week Low | 3.44 |
Average Volume | 1,707,005 |
200-Day Moving Average | 5.47 |
50-Day Moving Average | 5.01 |
20-Day Moving Average | 3.86 |
10-Day Moving Average | 3.70 |
Average True Range | 0.25 |
RSI (14) | 28.57 |
ADX | 35.72 |
+DI | 12.13 |
-DI | 29.95 |
Chandelier Exit (Long, 3 ATRs) | 3.83 |
Chandelier Exit (Short, 3 ATRs) | 4.20 |
Upper Bollinger Bands | 4.25 |
Lower Bollinger Band | 3.47 |
Percent B (%b) | 0.04 |
BandWidth | 20.27 |
MACD Line | -0.34 |
MACD Signal Line | -0.40 |
MACD Histogram | 0.0534 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 3.89 | ||||
Resistance 3 (R3) | 3.91 | 3.81 | 3.83 | ||
Resistance 2 (R2) | 3.81 | 3.71 | 3.80 | 3.80 | |
Resistance 1 (R1) | 3.65 | 3.65 | 3.60 | 3.63 | 3.78 |
Pivot Point | 3.55 | 3.55 | 3.52 | 3.54 | 3.55 |
Support 1 (S1) | 3.39 | 3.45 | 3.34 | 3.37 | 3.22 |
Support 2 (S2) | 3.29 | 3.39 | 3.28 | 3.20 | |
Support 3 (S3) | 3.13 | 3.29 | 3.18 | ||
Support 4 (S4) | 3.11 |